AER Therapeutics
$56.9Mtotal raised · 4 rounds on record
$5Mlatest round · Venture round · Jan 2025 · 21 mo ago
2backers · Canaan Partners, OrbiMed
50+team · employees, estimated range
Overview
AER Therapeutics is developing mucolytic treatments that target mucus plugs in COPD and asthma to improve lung function and quality of life.
Key facts
These are the key facts about AER Therapeutics on Alion as of Nov 13, 2026. AER Therapeutics is headquartered in Raleigh, United States. It has raised $56.9M in 3 funding rounds. The latest round is Venture - Series Unknown of $5M, announced in 2025.
- Headquarters
- Raleigh, United StatesAlion company profile, updated Oct 11, 2026
- Employees
- 50+Alion company profile, an estimated range
- Total raised
- $56.9MSum of 3 equity rounds Alion knows
- Latest round
- Venture - Series Unknown · $5M · Jan 24, 2025SEC Form D filing · sec.gov
Official records
Funding and backers
Total raised
$56.9M
4 rounds on record
Latest round
$5M
Venture round · Jan 2025 · 21 mo ago
Team
51-200
employees, estimated range
Backers
2
Canaan Partners, OrbiMed
The money's age
Due for its next round
21 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 19
Board appointment Evan Caplan, Director · SEC Form D
Aug 7
Took on debt financing $3M · SEC Form D
Jan 24, 2025
Raised a round Venture round $5M · SEC Form D
Apr 13, 2023
Raised a round Series A $36M
Dec 9, 2022
Raised a round Venture round $15.9M · SEC Form D
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Debt Financing | Aug 2026 | $3M | — | SEC Form D |
| Venture round | Jan 2025 | $5M | — | SEC Form D |
| Series A | Apr 2023 | $36M | — | wlns.com |
| Venture round | Dec 2022 | $15.9M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Aer Therapeutics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
James ShafferExecutive Officer, DirectorSEC Form D
Thomas MathersExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
-Our Mission 誰もが空の恩恵を享受できる世界を実現する トラジェクトリーは、管制の自動化を通じて、誰もが安全かつ簡単に無人航空機の恩恵を享受できる社会を実現し、人々のQOL（Quality of Life）の向上に貢献するというミッションを掲げています。.
Advancing treatments to improve outcomes and quality of life for patients with hypertrophic cardiomyopathy and related heart conditions.
We believe that clinical remission should be the standard—not the exception—for treating chronic inflammatory diseases like COPD, asthma…
Medical Device Developmentto Enhance the Quality of Life. 再生医療機器開発.
Alpheus is advancing a new therapeutic approach designed to improve outcomes while reducing treatment burden for patients and families.
OCON Therapeutics. Our mission is to introduce an innovative, high-quality intrauterine drug-delivery technology to improve and impact…
People
James Shaffer
Executive Officer, Director
Thomas Mathers
Executive Officer, Director
Tim Shannon
Director
Christy Shaffer
Director
Rishi Gupta
Director
John Fahy
Director
Evan Caplan
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Canaan PartnersVia a fund
OrbiMedVia a fund
196 portfolio companies: Cookiedatabase.org, ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., Z-Alpha Therapeutics and 193 more
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Aer Therapeutics to Present at the Reagan-Udall Foundation for the FDA Meeting
Advancing Drug Development by Reducing Reliance on Animal Testing. Case Example: Pre-Clinical Animal Models in Lung Toxicology. Aer Therapeutics, a biopharmaceutical company developing novel inhaled treatments for mucus-associated lung disease, is present
Read more
Report
Aer Therapeutics to Participate at Cantor Global Healthcare Conference
DURHAM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) - Aer Therapeutics ("Aer"), a biopharmaceutical company developing novel inhaled treatments for mucus-associated lung disease, announced today that Thomas P. Mathers, Executive Chairman of Aer, will participate
Read more
Report
Aer Therapeutics to Participate at Cantor Global Healthcare Conference
DURHAM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aer Therapeutics (
Read more
Report
Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial
Study AER-01-002 is using a novel and precision imaging strategy to enroll 100 mucus plug-high chronic obstructive pulmonary disease (COPD) patients AER-01-002 is well powered to determine if 28-days of once daily dosing of fexlamose is safe and improves
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Raleigh
United States
HQ
50-200 est. staff
400 W North Street,, Suite 112, Raleigh NC 27603
How to cite this page
Alion, "AER Therapeutics: key facts", as of Nov 13, 2026. https://alion.io/company/world-12
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0